ArticleFrontiers in cardiovascular medicine2025
The role of complement C1q in atrial fibrillation: a marker for disease progression and surgical outcomes.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between atrial fibrillation and age-related macular degeneration: A nationwide cohort study.Eye (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: The complement system plays a crucial role in the pathogenesis and progression of cardiovascular diseases. C1q, a key initiator of the classical pathway, is closely associated with various chronic inflammatory conditions. This observational study aims to elucidate the potential risk relationship between serum complement C1q levels and atrial fibrillation (AF). Materials and methods: This retrospective cohort study included 812 AF patients treated at the Affiliated Hospital of Qingdao University from January 2020 to October 2022, comprising 694 patients in the paroxysmal AF group and 118 in the persistent AF group. Serum complement C1q levels were measured using an enzyme-linked immunosorbent assay (ELISA). Results: Serum C1q levels in the AF group were significantly lower than those in the control group ( Conclusion: Serum C1q levels are significantly reduced in patients with AF. The presence of CFAE in the superior left atrium of paroxysmal AF patients may be potentially associated with C1q levels. Low complement levels are associated with atrial fibrillation compared to individuals without AF and may represent a potential underlying cause of impaired sinus rhythm maintenance following pulmonary vein isolation. Complement C1q may play a critical role in the pathogenesis of AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.